Data Sheet (Cat.No.T2272)



BPR1J-097

Chemical Properties


CAS No.: 1327167-19-0

Formula: C27H28N6O3S

Molecular Weight: 516.61

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	BPR1J-097) is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM).			
Targets(IC50)	FLT			
Kinase Assay	Kinase assays: To assay Plk1 and Aurora A kinase activity, cells are lysed after 13 hrs release in the presence of SBE13 after double thymidine block, and kinases are immunoprecipitated from lysates using antibodies as described. In brief, for each immunoprecipitation 800 μg of total protein were incubated with 1.5 μg Plk1 antibody cocktail, 3 μg Plk2 antibody, 3 μg Plk3 antibody, or 5 μg Aurora A antibody, respectively, for 2 hrs at 4°C on a rotator. Immunoprecipitated protein is collected using Protein G Agarose beads. The Plk1, Plk2 and Plk3 immunoprecipitates are incubated with 1 μg casein and with 1 μCi of [γ32-P]ATP for 30 min at 37°C in kinase buffer. The Aurora A immunoprecipitates are incubated with 0.5 μl Histone and with 1 μCi of [γ32-P]ATP for 60 min at room temperature in kinase buffer. Products from the kinase assays are fractionated on 10% Bis-Tris-polyacrylamide gels, and the phosphorylated substrate is visualized by autoradiography after an exposure of 12 to 36 hrs. An equal amount of immunoprecipitates is subjected to western blot analysis to confirm equal loading of Plk1, Plk2, Plk3 or Aurora A protein in kinase reactions. Immunoprecipitated Plk1 after 13 hrs release in the presence of SBE13 is assayed after de-phosphorylation using λ protein phosphatase and compared to kinase activity of endogenous immunoprecipitated Plk1. Activity of Plk1 kinase with and wiiiuithout de-phosphorylation is compared and the ratio between de-phosphorylated and "normal" endogenous immunoprecipitated Plk1			
	kinase activity is calculated.			

Solubility Information

(< 1 mg/ml refers to the product slightly soluble or insoluble)	Solubility	DMSO: 11 mg/mL (21.29 mM),Sonication is recommended.
(3 Ting/introduct stignity soluble of insoluble)		(< 1 mg/ml refers to the product slightly soluble or insoluble)

Page 1 of 2 www.targetmol.com

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9357 mL	9.6785 mL	19.357 mL
5 mM	0.3871 mL	1.9357 mL	3.8714 mL
10 mM	0.1936 mL	0.9678 mL	1.9357 mL
50 mM	0.0387 mL	0.1936 mL	0.3871 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Lin WH, et al. Br J Y. 2012 Jan 31;106(3):475-81.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com